ValuEngine Downgrades Kazia Therapeutics (NASDAQ:KZIA) to Sell

Kazia Therapeutics (NASDAQ:KZIA) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday, ValuEngine reports.

Separately, Zacks Investment Research cut shares of Kazia Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 3rd.

NASDAQ KZIA traded up $0.07 during trading hours on Monday, reaching $3.22. The company’s stock had a trading volume of 329 shares, compared to its average volume of 4,852. The stock has a market cap of $20.72 million, a PE ratio of -3.32 and a beta of 1.63. Kazia Therapeutics has a fifty-two week low of $2.04 and a fifty-two week high of $4.27. The company’s 50-day moving average is $3.15 and its two-hundred day moving average is $2.92.

A hedge fund recently bought a new stake in Kazia Therapeutics stock. Citadel Advisors LLC acquired a new stake in Kazia Therapeutics Ltd (NASDAQ:KZIA) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 20,473 shares of the company’s stock, valued at approximately $49,000. Citadel Advisors LLC owned about 0.33% of Kazia Therapeutics at the end of the most recent quarter. 3.66% of the stock is currently owned by institutional investors and hedge funds.

About Kazia Therapeutics

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops therapies for a range of oncology indications. Its lead product is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway that is in Phase II clinical trials to treat glioblastoma multiforme. The company is also developing TRX-E-002-1 (Cantrixil), a third-generation benzopyran molecule, which is in Phase I clinical trials to treat ovarian cancer.

See Also: How is the discount rate different from the Federal Funds rate?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with's FREE daily email newsletter.